The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Balancing the benefits and toxicity of IO intensification in lung cancer
Xiao Wang, MD, Yale Cancer Center, New Haven, CT, comments on the potential benefits and pitfalls immunotherapy (IO) intensification in lung cancer. Whilst clinicians may agree that patients should receive the lest toxic therapy, a significant gap exists between ideal treatment recommendations and actual treatment practices, especially in patients with specific cancer mutations who received appropriate targeted therapy after genomic profiling. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In our trial, we found that patients with oligoprogressive disease could maintain the systemic treatment, immunotherapy and targeted therapy, and they didn’t change or start new systemic therapy to treat the oligoprogressive sites or cure the disease. So they maintained for more time the ongoing systemic treatment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video...
In our trial, we found that patients with oligoprogressive disease could maintain the systemic treatment, immunotherapy and targeted therapy, and they didn’t change or start new systemic therapy to treat the oligoprogressive sites or cure the disease. So they maintained for more time the ongoing systemic treatment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
